ONCO Stock Forecast: Onconetix, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.89
−8.54% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$2.6M
Ticker Nerd rank
16/ 100
Median analyst target
—
Analysts covering
—
Revenue$17K−83.9% y/y
Operating income−$2.2M
Net income−$2.9M
Free cash flow−$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.0%
1M
−28.8%
YTD
−99.6%
1Y
−99.8%
From 52W high
−99.8%
From 52W low
0.0%
$3
$1,495
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Onconetix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
16/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
66
Growth
34
Volatility
26
Quality
25
Issuance
24
Momentum
23
Revisions
20
Value
6

Accruals (66): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ONCO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ONCO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$500$1,000$1,500Jan 26Apr 26Jul 26Oct 26ONCO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Sept 2023Maxim GroupDowngradeHold—
26 Apr 2023HC Wainwright & Co.MaintainsBuy—
1 Feb 2023HC Wainwright & Co.ReiteratesBuy—
9 Dec 2022HC Wainwright & Co.InitiatesBuy—
8 Dec 2022Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ONCO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ONCO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Onconetix, Inc. returned −99.8% against +6.9% for the S&P 500, dividends included.

ONCO vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ONCOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ONCO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 99% of US stocks

Price / sales
5.3×

Cheaper than 20% of US stocks

Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
25.1%

Higher than 27% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−98.5%

Higher than 14% of US stocks

Return on assets
−24.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Onconetix, Inc. has a market value of $2.6M.

  • Revenue in the twelve months to 30 June 2026: $646K. The latest quarter shrank 83.9% year on year.

  • Net income over the same four quarters: −$10.2M, a −1578.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$10.3M.

  • Onconetix, Inc. spent $348.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 3.8M.

  • Trailing P/E: 0.0×.

  • Onconetix, Inc. employs 2 people — $323K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ONCO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ONCOOnconetix, Inc.$2.6M16
HCWBHCW Biologics Inc.$2.4M48
REVBRevelation Biosciences, Inc.$2.4M14
GRIGRI Bio, Inc.$2.4M24
PMCBPharmaCyte Biotech, Inc.$2.2M25
DRMADermata Therapeutics, Inc.$2.5M26
ERNAErnexa Therapeutics, Inc.$2.2M18

Take a look at ONCO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Onconetix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ONCO

How does Ticker Nerd's model rank ONCO?

As at 21 Nov 2026, Onconetix, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (66 of 100).

What is the ONCO stock forecast for 2030?

No analyst covering Onconetix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ONCO are extrapolating price history, which says nothing about the business.

How has ONCO stock performed over the past year?

Onconetix, Inc. returned -99.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Onconetix, Inc. do?

Onconetix Inc. is a commercial-stage biotechnology company focused on solutions for men’s health and oncology. The company develops and commercializes proprietary therapeutics, diagnostics, and clinician-focused services, with an emphasis on prostate cancer and related urologic conditions.

Company

About Onconetix, Inc.

Onconetix Inc. is a commercial-stage biotechnology company focused on solutions for men’s health and oncology. The company develops and commercializes proprietary therapeutics, diagnostics, and clinician-focused services, with an emphasis on prostate cancer and related urologic conditions. Its product portfolio includes Proclarix, a blood-based diagnostic test used in prostate cancer assessment, and Entadfi, an oral therapy for benign prostatic hyperplasia. Onconetix also works on expanding its oncology diagnostics and treatment offerings through research, development, and commercialization activities across key international markets, including the United States and Europe. Headquartered in Cincinnati, Ohio, Onconetix Inc. operates at the intersection of diagnostic testing and therapeutic care, serving healthcare providers and patients in specialized cancer and men’s health settings.

CEO Ms. Karina M. Fedasz · 2 employees · United States · https://www.onconetix.com